Grade: F — Major Red Flags
Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles
Data: SEC EDGAR 10-K (Filed 2026-02-20, FY ended December 28, 2025) + Yahoo Finance
Auditor: PricewaterhouseCoopers LLP — Unqualified opinion (1 critical audit matter: U.S. net sales revenue recognition)
One-line verdict: Kenvue is a $15.1B consumer health company — Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno — that J&J carved out in 2023 and is now the subject of a stock-for-stock merger with Kimberly-Clark. Organic sales declined 2.2% as trade inventory destocking, lower seasonal incidences, and skin health weakness pressured volume. The company recorded $290M in restructuring charges under its "Our Vue Forward" initiative, $23M in impairment charges, and $1.6B in dividends. Cash flow is healthy (CFFO/NI 1.49, FCF/NI 1.17) and the M-Score of -2.47 is clean. But three quantitative fails — AR outpacing revenue for two consecutive years, cash covering 12% of $8.7B in debt, and goodwill plus intangibles at 169% of equity — drive the F grade. The Skin Health & Beauty reporting unit's goodwill exceeded carrying value by only 10%, with a 100bp discount rate increase potentially triggering impairment.
| Metric | Result |
|---|---|
| Red Flags | **3** (AR outpacing revenue 2 years, cash covers 12% of debt, goodwill+intangibles 169% of equity) |
| Watch Items | **0** |
| Checks Completed | **18/18** |
| Beneish M-Score | **-2.47** (clean; threshold is -2.22) |
| Altman Z-Score | **1.21** (grey zone — concerning) |
| Auditor | PwC LLP — Unqualified opinion, 1 critical audit matter |
The Business: J&J's Consumer Health Legacy
Kenvue was separated from Johnson & Johnson through an IPO in May 2023 and full separation via exchange offer in August 2023. The company operates three segments: Self Care ($5.6B — Tylenol, Motrin, Zyrtec, Nicorette), Skin Health and Beauty ($4.2B — Neutrogena, Aveeno, Dr.Ci:Labo), and Essential Health ($5.3B — Listerine, Band-Aid, Johnson's Baby).
Per the filing, the Kimberly-Clark merger was announced November 2, 2025: a stock-for-stock combination. The company faces acetaminophen and talc litigation exposure inherited from J&J.
Profitability: Volume Decline, Margins Hold
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Trend |
|---|---|---|---|---|---|
| Net Sales | $14.9B | $15.4B | $15.5B | $15.1B | -2.1% YoY |
| Net Income | $2.06B | $1.66B | $1.03B | $1.47B | +43% YoY (FY2024 depressed by Dr.Ci:Labo impairment) |
| Gross Margin | 55.4% | 56.0% | 58.0% | 58.1% | Expanding |
| Operating Income | — | $2,512M | $1,841M | $2,414M | +31% YoY |
The 58.1% gross margin is premium for consumer staples, reflecting Kenvue's healthcare-adjacent product portfolio. Organic sales declined 2.2%, driven by "volume-related decreases of 2.3% partially offset by favorable value realization of 0.1%." Volume declines were caused by "trade inventory reductions driven by retailer inventory management in the United States and changes in shipment timing in China, as well as lower seasonal incidences impacting Allergy Care, pediatric Pain Care, and Cough and Cold."
FY2024 net income was depressed by a $488M Dr.Ci:Labo impairment and $68M corporate headquarters impairment. FY2025 impairments were just $23M (ORSL trade name in India).
Cash Flow: Healthy Generation
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating Cash Flow | $3.17B | $1.77B | $2.20B |
| Net Income | $1.66B | $1.03B | $1.47B |
| **CFFO / Net Income** | **1.90** | **1.72** | **1.49** |
| CapEx | $0.47B | $0.43B | $0.48B |
| Free Cash Flow | $2.70B | $1.33B | $1.72B |
FY2023 CFFO was elevated by J&J separation-related working capital flows ($1.45B in accounts payable/accrued liabilities). Normalizing for this, FY2025's $2.2B CFFO represents the company's steady-state cash generation. Dividends of $1.58B consumed 92% of FCF. Share repurchases of $197M were modest.
The 18-Point Screening
Revenue Quality
| # | Check | Result | Detail |
|---|---|---|---|
| A1 | DSO Change | PASS | DSO 57 days, +6 days YoY |
| A2 | AR vs Revenue Growth | FAIL | AR outpaced revenue for 2 consecutive years |
| A3 | Revenue vs CFFO | PASS | Revenue -2.1%, CFFO +24.2% |
A2 — Persistent AR divergence. Two consecutive years of AR growing faster than revenue is a revenue quality flag. Trade receivables increased $112M while net sales declined $331M. This could reflect loosening payment terms to maintain shelf space, timing shifts, or customer mix changes. PwC identified U.S. net sales revenue recognition as a critical audit matter, applying "a high degree of auditor effort" to testing trade promotions, credit memos, and settlement of invoices.
Expense Quality
| # | Check | Result | Detail |
|---|---|---|---|
| B1 | Inventory vs COGS | PASS | Inventory +4.7% vs COGS -2.5%. Normal |
| B2 | CapEx vs Revenue | PASS | CapEx +9.4% vs revenue -2.1%. Normal |
| B3 | SG&A Ratio | PASS | SG&A/Gross Profit = 69.2%. Normal |
| B4 | Gross Margin | PASS | 58.1%, +0.1pp. Stable |
Cash Flow Quality
| # | Check | Result | Detail |
|---|---|---|---|
| C1 | CFFO vs Net Income | PASS | CFFO/NI = 1.49. Profits backed by cash |
| C2 | Free Cash Flow | PASS | FCF $1.72B, FCF/NI = 1.17 |
| C3 | Accruals Ratio | PASS | -2.7%. Low accruals |
| C4 | Cash vs Debt | FAIL | Cash $1.1B covers only 12% of debt $8.7B |
C4 — Heavy debt inherited from J&J. Long-term debt of $7.1B plus current portion of $1.5B. The debt was largely incurred during the J&J separation to fund the $13.8B distribution to J&J. Interest expense of $379M annually is a significant fixed cost.
Balance Sheet
| # | Check | Result | Detail |
|---|---|---|---|
| D1 | Goodwill + Intangibles | FAIL | $18.2B = 169% of equity |
| D2 | Leverage | PASS | Debt/EBITDA = 2.9x. Healthy |
| D3 | Soft Asset Growth | PASS | Other assets +0.1% vs revenue -2.1% |
| D4 | Asset Impairment | PASS | Write-offs normal |
D1 — Massive intangible base. Goodwill and intangibles of $18.2B dwarf total equity of $10.8B. These intangibles were recorded at fair value when J&J transferred the Consumer Health Business to Kenvue. The Skin Health and Beauty reporting unit is at particular risk: fair value exceeded carrying value by only approximately 10%, and per the filing, "an increase of approximately 100 basis points in the selected discount rate would have resulted in an impairment charge."
Acquisition Risk
| # | Check | Result | Detail |
|---|---|---|---|
| E1 | Serial Acquirer FCF | PASS | FCF after acquisitions positive |
| E2 | Goodwill Surge | PASS | Goodwill+Intangibles +5% YoY. Normal |
Manipulation Score
| # | Check | Result | Detail |
|---|---|---|---|
| F1 | Beneish M-Score | PASS | -2.47 (threshold: < -2.22) |
Key Risks from the 10-K
1. Skin Health and Beauty Goodwill Near Impairment Threshold
The Skin Health and Beauty reporting unit exceeded carrying value by only ~10%. The filing warns: "A decline in forecasted Net sales or net income, or adverse macroeconomic developments such as rising interest rates, could significantly reduce the excess between fair value and carrying value." The FY2024 Dr.Ci:Labo impairment of $488M demonstrates the real risk here.
2. Kimberly-Clark Merger Uncertainty
The stock-for-stock merger with Kimberly-Clark creates integration risk, regulatory approval uncertainty, and potential management distraction. The combined entity would span consumer health and household products — very different go-to-market models and supply chains.
3. Acetaminophen and Talc Litigation
Inherited from J&J, these product liability claims represent material contingent liabilities. The filing lists "legal proceedings relating to acetaminophen and talc or talc-containing products" as forward-looking risk factors.
4. Our Vue Forward Restructuring Costs
Restructuring expenses of $290M in FY2025 (up from $185M in FY2024) relate to information technology and project costs under the "Our Vue Forward" initiative. Total restructuring spending continues to escalate as the company builds standalone capabilities post-J&J separation.
5. China Market Deterioration
Volume declines in China impacted both Self Care and Skin Health segments. The filing cites "shifts in consumer sentiment in China, as well as changing shopping patterns in the region" as factors behind the FY2024 Dr.Ci:Labo impairment. China exposure remains a headwind.
Summary
Grade: F. Three quantitative fails — AR divergence, thin cash coverage, and massive intangible overhang — on a recently independent company carrying J&J separation debt and facing a merger with Kimberly-Clark.
Kenvue's core consumer health franchise is high-quality: 58.1% gross margins, iconic brands (Tylenol, Listerine, Band-Aid), and CFFO/NI of 1.49. The M-Score of -2.47 is clean and accruals are low. PwC issued an unqualified opinion, though the critical audit matter on U.S. revenue recognition deserves attention alongside the AR divergence flag.
The structural issues are inherited: $8.7B in debt from the J&J separation, $18.2B in intangibles recorded at separation fair values, and a Skin Health segment one discount rate move from impairment. The pending Kimberly-Clark merger adds a layer of uncertainty. Kenvue is a strong consumer health business inside a fragile financial structure, heading into a transformative deal.
**Disclaimer**: This report is based on Kenvue Inc.'s FY2025 10-K filed with SEC EDGAR on February 20, 2026. This is NOT investment advice.
Data: SEC EDGAR 10-K + Yahoo Finance
Auditor: PricewaterhouseCoopers LLP (Unqualified opinion, 1 critical audit matter)
Fiscal year ended: December 28, 2025